The White Aisle Foundation was established to honor the life of Rebecca Garrison-Sokoloff, founder and owner of The White Aisle, who died of melanoma on November 13, 2011. The foundation raises funds for melanoma research and patient support, as well as for other charities that Rebecca supported during her life.
Rebecca's Boston Birthday Celebration
Thursday, September 24
100 Warrenton St.
Complimentary hors d'oeuvres
Silent auction and raffle
Join us at Venu, one of the hottest clubs in Rebecca's favorite city, to celebrate her birthday with an evening of food, drinks, and fun.
Fall Harvest Fest
Sunday, September 27, 2015
Silent auction and hors d'oeuvre reception begin at noon
Sit-down meal at 1 p.m.
Gather with friends around the table at Acacia to share Chef Chris Voigtsberger's delicious and innovative dishes created from the bounty of local farms. Enjoy a luscious family-style harvest meal together with wine and River Horse craft beer,
while supporting melanoma research.
NJ Social Affairs permit number 21462
A huge thanks to everyone who supported this year's Move against Melanoma campaign. We have raised more than $9,000 so far this spring for melanoma research.
In the news...
New clinical trial to study sequencing of melanoma drugs
Dr. Michael Atkins, who led team that treated Rebecca at Beth Israel and is now deputy director of Georgetown University Medical Center's Lombardi Comprehensive Cancer Center, will lead a new national clinical trial that compares the sequencing of two groups of melanoma drugs. The study will be conducted by the ECOG-ACRIN Cancer Research Group, of which Beth Israel is a member, and will recruit from cancer centers nationwide.
Quoted in a Georgetown press release, Dr, Atkins noted, “After many years of research, we’ve ended up with exciting and effective new combination treatment regimens. Now we need to figure out how to sequence these treatment regimens in order to best extend the lives of our patients.”
Atkins continued, “We have an approved two-drug combination, dabrafenib and trametinib, which works by directly attacking BRAF-mutated melanomas. We also have two immunotherapy options, ipilimumab and nivolumab, each approved for separate use, that work in combination to unleash the body’s own immune system to attack the cancer. The question that remains is which of the two drug combinations should be used first and in whom?”
Read the complete press release.